An In Vivo Technique to Track Bispecific Antibody-Induced T Cell Trafficking to Tumors
내레이션 대본
Take an anesthetized, immunocompromised mouse bearing a subcutaneous tumor xenograft that overexpresses a tumor-associated antigen or TAA.
Retroorbitally inject effector T cells expressing the luciferase enzyme.
Subcutaneously administer interleukin 2, a cytokine supporting effector T cell survival.
Retroorbitally inject bispecific antibodies engineered to contain binding sites for T and tumor cells. Allow the mouse to recover.
The antibodies and T cells reach the tumor via circulation.
The antibodies bind to CD3 on the T cells and TAA on the tumor cells, inducing the effector T cells to release toxins that initiate apoptosis in the tumor cells and release chemokines that recruit more T cells to the tumor.
Anesthetize the mouse, retroorbitally inject a luciferase substrate, and proceed to in vivo imaging.
Luciferase inside the T cells oxidizes the substrate, emitting bioluminescence.
Observe the bioluminescence over time. The magnitude of the signal correlates with the extent of T cell infiltration within the tumor.
